Abstract
Alexander et al from the Mayo Clinic in Rochester report the results of the first double-blind, randomized, placebo-controlled 6-week trial of 880-μg aerosolized fluticasone twice-a-day therapy in 42 adults with eosinophilic esophagitis. The complete dysphagia response with fluticasone by intention-to-treat analysis was 42.9% and was not statistically different from 28.6% with placebo. This was a negative study for the primary end point of dysphagia relief, despite a strongly positive result for the secondary end point of decreased esophageal eosinophilia with complete response in 61.9% of the fluticasone group and 0 in the placebo group (shown in the Figure 1).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
